Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

botensilimab (AGEN1181)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Agenus

Drug class:

CTLA4 antagonist

Related drugs:

No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: B - Late Trials AGEN2034 + AGEN1181 Sensitive : B	AGEN2034 + AGEN1181 Sensitive: B - Late Trials AGEN2034 + AGEN1181 Sensitive : B
PD-L1 expression	Colorectal Cancer	PD-L1 expression	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials AGEN2034 + AGEN1181 Sensitive : C3	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials AGEN2034 + AGEN1181 Sensitive : C3
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials AGEN2034 + AGEN1181 Sensitive : C3	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials AGEN2034 + AGEN1181 Sensitive : C3
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials AGEN2034 + AGEN1181 Sensitive : C3	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials AGEN2034 + AGEN1181 Sensitive : C3